Walgreens has been sued by Arkansas Attorney General Leslie Rutledge, and the case was filed earlier this week. In her filing, she claimed that the pharmacy chain company played a big part in making the opioid crisis situation in the state worse.
Rutledge accused Walgreens of rendering a large number of orders for painkillers, and most of them are suspicious. The lawyer said that this is a violation of Arkansas’ Deceptive Trade Practices Act.
The lawsuit against Walgreens
The lawsuit was filed in Pulaski County Court, and it was stated that the pharmacy did not do enough to make sure that the prescriptions are legitimate and not questionable. It was said that because of Walgreens' failure to monitor the orders, large amounts of the regulated drug were distributed in Arkansas, as per Arkansas Democrat Gazelle.
"Walgreens has a legal responsibility to report suspicious orders and suspicious prescriptions," the attorney general said. "By failing to do so they enabled the black market of prescription drugs to increase dramatically, thus leading to more, greater addiction and more lives lost in the state of Arkansas."
As stated in the lawsuit, from 2006 to 2014, Walgreens fulfilled orders of over 142 million dosages of oxycodone and hydrocodone in the state. Rutledge said that this big amount should have alerted the company to the fact that suspicious orders were being placed.
It was added that such quantities that were distributed in Arkansas far exceeded the normal amount that could be consumed for medical legit purposes. “Walgreens failed to report and halt those orders and instead increased the number of pills distributed,” the statement from the suit reads.
With the filing, the state is seeking a directive that will force Walgreens to act responsibly and comply with federal and state laws. It is also seeking appropriate civil penalties for every violation that the company may have committed against the state’s consumer protection laws.
Walgreens denies the allegations
Walgreens refuted the accusations and stated that it never produced or marketed opioids. The company’s spokesperson further told FOX Business that they never sold the said drug to pain clinics, online pharmacies, and 'pill mills' that worsened the opioid crisis.
"Prior to 2014, we delivered opioids only to our own pharmacies, and the only place we ever sold FDA-approved opioid medications was at the pharmacy counter when presented with valid prescriptions written by DEA-licensed physicians for legitimate medical needs," the firm’s spokesperson said.
Finally, he added that the company’s pharmacists always evaluate and take the law into consideration before deciding whether to fill a prescription for controlled substances.


Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford
One Percent Rule Checklist For Safer Forex Trading Risk
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 



